Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From X4 Pharmaceuticals
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
Hologic’s recent buy-outs put it in a strengthened growth and competitive position beyond COVID.
Hologic’s acquisition of Somatex Medical will expand its biopsy portfolio and direct channel in Germany.
- Chiral Chemistry
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
- Synthesis Technologies, Production Processes
Drug Discovery Tools
- Molecular Diversity